Michael G. Natchus

6.5k total citations · 2 hit papers
69 papers, 2.9k citations indexed

About

Michael G. Natchus is a scholar working on Molecular Biology, Epidemiology and Oncology. According to data from OpenAlex, Michael G. Natchus has authored 69 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 24 papers in Epidemiology and 19 papers in Oncology. Recurrent topics in Michael G. Natchus's work include Respiratory viral infections research (17 papers), Protease and Inhibitor Mechanisms (13 papers) and Peptidase Inhibition and Analysis (12 papers). Michael G. Natchus is often cited by papers focused on Respiratory viral infections research (17 papers), Protease and Inhibitor Mechanisms (13 papers) and Peptidase Inhibition and Analysis (12 papers). Michael G. Natchus collaborates with scholars based in United States, Germany and Slovakia. Michael G. Natchus's co-authors include George R. Painter, Tomáš Hudlický, Richard K. Plemper, Alexander A. Kolykhalov, G. SINAI‐ZINGDE, Neil G. Almstead, Yetunde O. Taiwo, Gregory R. Bluemling, Jeong-Joong Yoon and Biswanath De and has published in prestigious journals such as Science, Journal of the American Chemical Society and Nature Communications.

In The Last Decade

Michael G. Natchus

68 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Small-Molecule Antiviral β- d - N ⁴ -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance

2019 255 citations Maria L. Agostini, Andrea J. Pruijssers et al. Journal of Virology profile →
Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia

2019 233 citations Märt Toots, Jeong-Joong Yoon et al. Science Translational Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael G. Natchus United States	29	1.0k	879	744	585	531	69	2.9k
Kent D. Stewart United States	34	559 0.6×	1.3k 1.4×	967 1.3×	518 0.9×	469 0.9×	91	3.1k
Michele Connelly United States	30	661 0.7×	1.6k 1.9×	452 0.6×	486 0.8×	763 1.4×	66	3.1k
Maria Paola Costi Italy	31	341 0.3×	1.7k 1.9×	850 1.1×	602 1.0×	499 0.9×	171	3.3k
Torsten Steinmetzer Germany	33	1.1k 1.1×	1.5k 1.7×	454 0.6×	630 1.1×	525 1.0×	137	3.8k
Arlene S. Bridges United States	31	495 0.5×	1.2k 1.4×	413 0.6×	470 0.8×	647 1.2×	53	3.1k
Walter Fast United States	32	509 0.5×	1.7k 1.9×	360 0.5×	405 0.7×	333 0.6×	80	3.5k
Arnab K. Chatterjee United States	30	444 0.4×	1.7k 1.9×	1.0k 1.4×	379 0.6×	319 0.6×	76	3.5k
Lars Petter Jordheim France	27	597 0.6×	1.7k 1.9×	524 0.7×	370 0.6×	627 1.2×	109	3.1k
Zhenyu Li China	27	419 0.4×	1.3k 1.5×	744 1.0×	208 0.4×	430 0.8×	111	2.6k

Countries citing papers authored by Michael G. Natchus

Since Specialization

Citations

This map shows the geographic impact of Michael G. Natchus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael G. Natchus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael G. Natchus more than expected).

Fields of papers citing papers by Michael G. Natchus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael G. Natchus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael G. Natchus. The network helps show where Michael G. Natchus may publish in the future.

Co-authorship network of co-authors of Michael G. Natchus

This figure shows the co-authorship network connecting the top 25 collaborators of Michael G. Natchus. A scholar is included among the top collaborators of Michael G. Natchus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael G. Natchus. Michael G. Natchus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Westover, Jonna B., Kevin W. Bailey, Alexander A. Kolykhalov, et al.. (2025). Effective treatment of advanced Oropouche virus, Rift Valley fever virus, and Dabie bandavirus infections with 4'-fluorouridine. mBio. 16(10). e0146725–e0146725.

Lieber, Carolin M., Megha Aggarwal, Nicole A. P. Lieberman, et al.. (2024). Influenza A virus resistance to 4’-fluorouridine coincides with viral attenuation in vitro and in vivo. PLoS Pathogens. 20(2). e1011993–e1011993. 4 indexed citations

Cox, Robert M., Carolin M. Lieber, Josef D. Wolf, et al.. (2023). Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models. Nature Communications. 14(1). 4731–4731. 18 indexed citations

Bluemling, Gregory R., Michael G. Natchus, Wendy Painter, et al.. (2022). The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N-Hydroxycytidine (EIDD-1931) in a mouse model of lethal Ebola virus infection. Antiviral Research. 209. 105453–105453. 9 indexed citations

Lieber, Carolin M., Robert M. Cox, Julien Sourimant, et al.. (2022). SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model. Nature Communications. 13(1). 4416–4416. 33 indexed citations

Painter, George R., et al.. (2021). Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19. Current Opinion in Virology. 50. 17–22. 112 indexed citations

Cox, Robert M., et al.. (2021). Therapeutic targeting of measles virus polymerase with ERDRP-0519 suppresses all RNA synthesis activity. PLoS Pathogens. 17(2). e1009371–e1009371. 12 indexed citations

Cox, Robert M., Julien Sourimant, Märt Toots, et al.. (2020). Orally efficacious broad-spectrum allosteric inhibitor of paramyxovirus polymerase. Nature Microbiology. 5(10). 1232–1246. 22 indexed citations

Toots, Märt, Jeong-Joong Yoon, Robert M. Cox, et al.. (2019). Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Science Translational Medicine. 11(515). 233 indexed citations breakdown →

10.

Painter, George R., Richard A. Bowen, Gregory R. Bluemling, et al.. (2019). The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. Antiviral Research. 171. 104597–104597. 81 indexed citations

11.

Agostini, Maria L., Andrea J. Pruijssers, James D. Chappell, et al.. (2019). Small-Molecule Antiviral β- d - N ⁴ -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance. Journal of Virology. 93(24). 255 indexed citations breakdown →

12.

Toots, Märt, Jeong-Joong Yoon, M. N. Hart, et al.. (2019). Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Translational research. 218. 16–28. 85 indexed citations

13.

Urakova, Nadya, Valeriya Kuznetsova, David K. Crossman, et al.. (2017). β- d - N ⁴ -Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome. Journal of Virology. 92(3). 148 indexed citations

14.

Moore, Terry W., Dan Yan, John M. Ndungu, et al.. (2013). Asymmetric synthesis of host-directed inhibitors of myxoviruses. Beilstein Journal of Organic Chemistry. 9. 197–203. 12 indexed citations

15.

Natchus, Michael G., et al.. (2008). MSX-122, an orally available small molecule CXCR4 antagonist, promotes leukocytosis in monkeys at doses that were well tolerated in a 28 day toxicology study. Cancer Research. 68. 1189–1189. 1 indexed citations

16.

Janusz, Michael J., Kimberly K. Brown, Lily C. Hsieh, et al.. (2006). Comparison of the pharmacology of hydroxamate- and carboxylate-based matrix metalloproteinase inhibitors (MMPIs) for the treatment of osteoarthritis. Inflammation Research. 55(2). 60–65. 12 indexed citations

17.

Laufersweiler, Matthew J., John C. VanRens, Michael G. Natchus, et al.. (2001). The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold. Bioorganic & Medicinal Chemistry Letters. 11(15). 1975–1979. 17 indexed citations

18.

Hudlický, Tomáš, et al.. (2001). Chemoenzymatic synthesis of functionalized cyclohexylglycines and α-methylcyclohexylglycines via Kazmaier–Claisen rearrangement. Bioorganic & Medicinal Chemistry Letters. 11(5). 627–629. 7 indexed citations

19.

De, Biswanath, Michael G. Natchus, Stanisław Pikul, et al.. (1999). The Next Generation of MMP Inhibitors: Design and Synthesis. Annals of the New York Academy of Sciences. 878(1). 40–60. 28 indexed citations

20.

Natchus, Michael G., Stanisław Pikul, Neil G. Almstead, et al.. (1998). Design and synthesis of conformationally-constrained MMP inhibitors. Bioorganic & Medicinal Chemistry Letters. 8(16). 2077–2080. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact